Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Carboplatin in Triple Negative Breast Cancer: NCT07413601 Clinical Landscape Report 2026
18 September 2026
NCT07413601 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Varnimcabtagene autoleucel in Mantle-Cell Lymphoma: NCT07412405 Clinical Landscape Report 2026
18 September 2026
NCT07412405 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dutasteride in Non-Muscle Invasive Bladder Neoplasms: NCT07420517 Clinical Landscape Report 2026
18 September 2026
NCT07420517 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
ITC-6146RO in Metastatic Solid Tumor: NCT07423117 Clinical Landscape Report 2026
18 September 2026
NCT07423117 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CTX-10726 in Hepatocellular Carcinoma: NCT07419841 Clinical Landscape Report 2026
18 September 2026
NCT07419841 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Penpulimab in Triple Negative Breast Cancer: NCT07419880 Clinical Landscape Report 2026
18 September 2026
NCT07419880 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
APG-3288 in Recurrent Follicular Lymphoma: NCT07424833 Clinical Landscape Report 2026
18 September 2026
NCT07424833 clinical landscape for Recurrent Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19/BCMA CAR-T Cell(Wuhan Union Hospital) in Relapse multiple myeloma: NCT07429721 Clinical Landscape Report 2026
18 September 2026
NCT07429721 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mesna in Osteosarcoma: NCT07428993 Clinical Landscape Report 2026
18 September 2026
NCT07428993 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Bladder Cancer: ACTRN12626000234314 Clinical Landscape Report 2026
18 September 2026
ACTRN12626000234314 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
cCTL(Obstetrics and Gynecology Hospital of Fudan University) in Female Genital Neoplasms: NCT07434284 Clinical Landscape Report 2026
18 September 2026
NCT07434284 clinical landscape for Female Genital Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Indocyanine Green in Carcinosarcoma: PACTR202602541023094 Clinical Landscape Report 2026
18 September 2026
PACTR202602541023094 clinical landscape for Carcinosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.